OncXerna Therapeutics Announces Final Results and New Xerna™ TME Panel Biomarker Data from a Phase 2 Trial of Bavituximab Plus Pembrolizumab in Patients with Previously Untreated Advanced Hepatocellular Carcinoma
23 janv. 2023 07h00 HE
|
OncXerna Therapeutics, Inc.
Bavituximab plus pembrolizumab combination achieved a 62.5% response rate in biomarker positive subgroup of hepatocellular cancer patients Data reinforce the potential of Xerna TME Panel to...
OncXerna Therapeutics Announces New Xerna™ TME Panel Biomarker Data from Retrospective Analysis of Results from a Randomized Phase 2 Trial Evaluating Anti-PD-1 Maintenance Therapy in Esophagogastric Adenocarcinoma at the ESMO Congress 2022
12 sept. 2022 07h00 HE
|
OncXerna Therapeutics, Inc.
Better 24-month survival was achieved when durvalumab was used for maintenance compared to surveillance in esophagogastric adenocarcinoma patients with “high” Xerna TME Panel immune scores, despite...
OncXerna Therapeutics Doses First Patient in Phase 2 Trial Evaluating Navicixizumab Alone or in Combination with Chemotherapy in Patients with Select Advanced Solid Tumors
08 sept. 2022 08h00 HE
|
OncXerna Therapeutics, Inc.
Multicenter basket trial includes cohorts enrolling patients with colorectal and triple negative breast cancer Trial designed to assess efficacy, safety, and evaluate the relationship between tumor...
OncXerna Therapeutics Announces Upcoming ASCO Poster Featuring Data Showing the Phase 2 Glioblastoma Trial of Bavituximab with Chemoradiation and Adjuvant Temozolomide Met its Primary Endpoint
03 juin 2022 08h00 HE
|
OncXerna Therapeutics, Inc.
Trial’s 73% twelve-month overall survival rate in newly diagnosed glioblastoma patients compares favorably to historical benchmark of 60% Results show median progression-free survival of 6.9 months...
OncXerna Therapeutics Announces Journal of Clinical Oncology Publication Featuring Phase 1b Data of Navicixizumab Plus Paclitaxel in Ovarian Cancer
21 avr. 2022 07h30 HE
|
OncXerna Therapeutics, Inc.
Overall response rate (ORR) of 43% and median duration of response of 6 months seen with navicixizumab-paclitaxel combination in heavily pretreated platinum-resistant ovarian cancer patients Xerna™...
OncXerna Therapeutics Highlights the Xerna™ TME Panel’s Prognostic and Predictive Value Across Indications and Therapeutic Classes at the AACR Annual Meeting
11 avr. 2022 07h00 HE
|
OncXerna Therapeutics, Inc.
AI-driven Xerna TME panel generates robust "binary-like" biomarker classifications that are prognostic across multiple tumor types Xerna TME Panel has potential to predict patient responses to...
OncXerna Therapeutics Announces New Biomarker Data from Retrospective Analysis of Results from Phase 1b Ovarian Cancer Trial of Navicixizumab Plus Paclitaxel at the ESGO 2021 Congress
23 oct. 2021 09h00 HE
|
OncXerna Therapeutics, Inc.
62% vs. 25% overall response rates with navicixizumab plus paclitaxel in biomarker positive vs. biomarker negative patients using the Xerna™ TME Panel 9.2 month vs. 3.9 month median progression...
OncXerna Therapeutics Announces New Phase 2 and Biomarker Data in Gastric Cancer from Bavituximab Program at the ESMO Congress 2021
16 sept. 2021 07h00 HE
|
OncXerna Therapeutics, Inc.
WALTHAM, Mass., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Oncxerna Therapeutics, Inc. (“OncXerna”), a precision medicine company using an innovative RNA-expression based biomarker platform to predict...
OncXerna Therapeutics Appoints C. Evan Ballantyne as Chief Financial Officer
17 août 2021 07h00 HE
|
OncXerna Therapeutics, Inc.
WALTHAM, Mass., Aug. 17, 2021 (GLOBE NEWSWIRE) -- OncXerna Therapeutics, Inc. (“OncXerna”), a precision medicine company using an innovative RNA-expression based biomarker platform to predict...
OncXerna Therapeutics to Present at The LifeSci Partners Private Company Summer Symposium
19 juil. 2021 07h00 HE
|
OncXerna Therapeutics, Inc.
WALTHAM, Mass., July 19, 2021 (GLOBE NEWSWIRE) -- OncXerna Therapeutics, Inc. (“OncXerna”), a precision medicine company using an innovative RNA-expression based biomarker platform to predict...